Bristol-Myers Squibb (NYSE:BMY) Stock Price Up 0.2%

Bristol-Myers Squibb (NYSE:BMY) shares rose 0.2% during mid-day trading on Tuesday . The company traded as high as $49.47 and last traded at $49.25. Approximately 1,272,055 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 15,421,163 shares. The stock had previously closed at $49.14.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Wells Fargo & Company lifted their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. Bank of America downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. Finally, StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Stock Down 0.3 %

The stock has a market capitalization of $99.03 billion, a price-to-earnings ratio of 12.66, a PEG ratio of 1.48 and a beta of 0.39. The firm’s fifty day moving average is $51.22 and its 200-day moving average is $51.31. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. The company had revenue of $11.48 billion for the quarter, compared to analysts’ expectations of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The firm’s revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.82 earnings per share. On average, sell-side analysts predict that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.91%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.18%.

Institutional Trading of Bristol-Myers Squibb

A number of large investors have recently modified their holdings of the company. OFI Invest Asset Management bought a new position in Bristol-Myers Squibb in the 3rd quarter valued at about $25,000. Milestone Investment Advisors LLC bought a new position in shares of Bristol-Myers Squibb during the 3rd quarter valued at about $27,000. Northwest Financial Advisors bought a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at about $27,000. Blue Bell Private Wealth Management LLC boosted its position in shares of Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 200 shares in the last quarter. Finally, Accordant Advisory Group Inc bought a new position in shares of Bristol-Myers Squibb during the 1st quarter valued at about $31,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.